16 results about "Ritonavir" patented technology

Methods of reducing hepatitis delta virus (HDV) viral loads in a patient are provided. In some embodiments, the method comprises treating the patient with lonafarnib-ritonavir co-therapy. In some embodiments, the method further comprises treating the patient with an interferon.

In alternative embodiments, provided are methods for treating, ameliorating, decreasing the chances of having any adverse effects from, decreasing the severity of adverse effects from a coronavirus infection, comprising administering to a subject or an individual in need thereof: (a) an anti-viral drug combination capable of killing a causative agent of the infection, or completely or partially inhibiting the ability of the causative agent of the infection to replicate or become infectious or cause pathology in the subject or the individual in need thereof, wherein the anti-viral drug combination comprises: (i) 1R,2S,5S)—N-[(1S)-1-cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(2S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido)butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide, and (ii) ritonavir; and, (b) an inactivated or attenuated agent of the infection, or a live, viable or infectious causative agent of the infection, or a live causative agent of the infection that is a completely or partially attenuated version of the causative agent, wherein at least one dosage of the anti-viral drug combination is administered to the subject or the individual in need thereof 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 or more days before, or on the day of, and / or is administered 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 or more days after, a first dose of the inactivated or attenuated agent of the infection.

The present invention discloses a drug preparation device containing ritonavir, which relates to the technical field of tablet manufacturing equipment, and comprises a base, a support frame is fixedly arranged at the top edge of the base, a motor is fixedly arranged at the top of the support frame, a driving shaft is fixedly arranged at the output end of the motor, the end of the driving shaft away from the motor is rotatably arranged at the top of the base, a medicine storage box is fixedly arranged on the side of the base, an inclined rod is fixedly arranged on the top of the medicine storage box, and a pressing mechanism comprises a follower arranged on one side of the driving shaft, a medicine feeding part arranged inside the top cylinder part, and a boss part arranged on one side of the base. The drug preparation device containing ritonavir changes the existing method of supplementing powder, and places the powder inside the top cylinder one. When the top cylinder one rotates with the rotating disk one, the powder is released in the closed space formed by the top head one, the top head two and the pressing hole, thereby avoiding the waste of powder.

Methods of reducing hepatitis delta virus (HDV) viral loads in a patient are provided. In some embodiments, the method comprises treating the patient with lonafarnib-ritonavir co-therapy. In some embodiments, the method further comprises treating the patient with an interferon.

The present application relates to a kind of combination drug composition for preventing or treating diffuse large B-cell lymphoma and its application, the active component of the combination drug composition is composed of first active component and second active component;The first active component is selected from selinexor or any one or at least two combinations of its pharmaceutically acceptable salt, isomer, solvate, metabolite;The second active component is selected from ritonavir or any one or at least two combinations of its pharmaceutically acceptable salt, isomer, solvate, metabolite.The combination drug composition has excellent treatment effect of diffuse large B-cell lymphoma, not only can reduce the dosage of selinexor, improve the safety of drug, but also has more significant inhibitory effect on diffuse large B-cell lymphoma than using single selinexor.

The application belongs to the technical field of pharmaceutical preparations, and discloses a liquid preparation containing nirmatrelvir and ritonavir as well as a preparation method and application thereof. The liquid preparation is prepared by combining nirmatrelvir, ritonavir and other excipients, has high absorption and high bioavailability, is accurate in dosing, and can accurately give a reasonable dose according to different symptoms. The application solves the problems of the existing Paxlovid tablet, such as large dose, inconvenience in taking, low dissolution, low bioavailability and the need to take multiple tablets, improves the medication compliance of patients, and reduces the drug toxicity. The preparation process of the liquid preparation containing nirmatrelvir and ritonavir is simple, and large equipment is not needed. The liquid preparation containing nirmatrelvir and ritonavir retains the medicinal properties of nirmatrelvir and ritonavir, and can be used for preparing a drug for novel coronavirus.

The invention provides a compound preparation of mofetidine and ritonavir and a preparation method of the compound preparation. Specifically, the invention provides a compound preparation. In some embodiments of the invention, the compound preparation comprises active ingredients, and the active ingredients comprise the mofetidine and the ritonavir. Compared with single-prescription Murfisidine and single-prescription Ritonavir, the compound preparation has the advantages that the curative effect of the medicine can be improved, and the side effects of the medicine can be reduced; in addition, the compound preparation is convenient to take, and the two medicines are combined into one preparation, so that the medication process of a patient can be simplified, and the compliance of the patient and the treatment convenience are improved; in addition, manufacturing of one compound preparation is more economical, more convenient and more efficient than manufacturing of two independent medicines, and cost and trouble for purchasing and using multiple medicines by a patient are reduced at the same time.

In alternative embodiments, provided are methods for treating, ameliorating, decreasing the chances of having any adverse effects from, decreasing the severity of adverse effects from, or preventing an infection, or boosting or enhancing natural immunity acquired by an infected individual, by administration of: an inactivated infectious causative agent of the infection, or an antibiotic and / or an anti-viral drugs and a vaccine directed to a causative agent of the infection and / or an attenuated and / or a live, viable or infectious causative agent of the infection. In alternative embodiments, the infection is bacterial or viral. In alternative embodiments, the viral infection is a coronavirus infection such a Covid-19 infection. In alternative embodiments, methods as provide herein prevent or decrease the prevalence or severity of “vaccine breakthrough infections” after vaccination, where external mutants of COVID-19 infect patients in spite of the fact that they have undergone immunization, for example, to prevent a mutant or variant COVID-19 infection. In alternative embodiments, an antiviral combination administered in coordination with a vaccine comprises PF-07321332 or PAXLOVID™ and / or ritonavir, or ivermectin, doxycycline and a zinc or a zinc salt. In alternative embodiments, methods as provided herein are used to prevent in vivo mutations of such mutant infectious agent to enhance the efficacy of an administered vaccination; in other words, methods as provided herein are used to prevent in vivo replication of an acquired viral mutant or variant infectious agent, and thus also prevents ongoing mutations of the viral infectious agent because using the combination antiviral co-therapy where there is no replication of infectious agent and so there is no possible further mutation of the infectious agent.

The present invention discloses a method for detecting an antiviral component and an application thereof. The detection method can detect five antiviral components, namely, monolavir, oseltamivir, daclatasvir, nematevir and ritonavir, at one time, with high sensitivity, strong specificity and good repeatability. The detection limit concentration of the five representative components is about 0.3 μg / ml, and the quantitative limit concentration is about 1 μg / ml. In addition, the recovery rate and the recovery of the spiked product are good. The method is simple and suitable for the rapid detection of antiviral components in medicines, is beneficial to the supervision and inspection of antiviral medicines, ensures the drug safety of consumers, and has broad application prospects.

Methods and compositions are provided for treating cancer in a taxane-resistant patient, comprising administering an effective amount of a taxane, either simultaneously or sequentially, with a P-gp inhibitor, such as ritonavir or a pharma- ceutically acceptable salt thereof. Also provided are methods and compositions for reversing taxane resistance in a patient, comprising administering an effective amount of a P-gp inhibitor, such as ritonavir or a pharma- ceutically acceptable salt thereof.

The present disclosure is related to a polymorphic form of ritonavir prepared by novel methods that require less time to produce the polymorphic form, the methods of preparing the polymorphic form, pharmaceutical compositions comprising the polymorphic form produced by the provided methods, and corresponding methods of treatment with the polymorphic form produced by the provided methods.

To provide compositions and kits of antiviral agents having different mechanisms of action for treating or preventing viral infections such as COVID-19 (also known as SARS-CoV-2) and for reducing medical complications related to COVID-19 viral disease.SOLUTION: A pharmaceutical composition for treating COVID-19 is provided, comprising: a first antiviral agent consisting of a picornavirus 3C protease inhibitor or a pharmaceutically acceptable salt thereof in a therapeutically effective amount; a second antiviral agent consisting of ritonavir or a pharmaceutically acceptable salt thereof in a therapeutically effective amount and having a different mechanism of action; and a third antiviral agent selected from a group consisting of dexamethasone and remdesivir.SELECTED DRAWING: None

The present invention discloses a high drug-loading ritonavir solid dispersion with good dissolution performance and a preparation method thereof. The solid dispersion is made of the following components in mass percentages: 35-55% of ritonavir, 11.2-33.75% of hypromellose E50, and the balance of povidone K30. The solid dispersion provided by the present invention can effectively inhibit the crystal nucleation and growth of the drug in the supersaturated solution and improve the stability of the active drug in the solid-liquid interfacial layer. The present invention breaks through the release consistency concentration limit of the original solid dispersion and provides a new idea for the preparation or process innovation of high drug-loading ritonavir tablets.

The present disclosure is related to a polymorphic form of ritonavir prepared by novel methods that require less time to produce the polymorphic form, the methods of preparing the polymorphic form, pharmaceutical compositions comprising the polymorphic form produced by the provided methods, and corresponding methods of treatment with the polymorphic form produced by the provided methods.

The invention discloses a method for detecting the concentration of four SARS-CoV-2 drugs based on HPLC-MS / MS, wherein the four SARS-CoV-2 drugs are ritonavir, namatevir, azithromycin and baricitinib, and the method comprises: obtaining standard curve working solutions of the four drugs respectively by an external standard method; detecting the sample test solution by HPLC-MS / MS, and quantifying the drug content by using the standard curve, wherein the chromatographic column is ACE Excel 2 C18–PFP; mobile phase A is 0.01% formic acid aqueous solution; mobile phase B is 0.01% formic acid acetonitrile solution; strong wash solution is 80% methanol; gradient elution time is 3 min. The invention is a highly sensitive and specific detection method based on HPLC-MS / MS: the method requires a short time, only 3 min, and greatly saves time for experiments with large sample sizes.

The present invention relates to the field of medical and chemical and pharmaceutical industry, and more particularly, to a novel pharmaceutical composition for treating and / or preventing viral diseases by inhibiting the activity of a viral 3CL protease, in particular a coronavirus 3CL protease, and a drug comprising the same, the pharmaceutical composition comprises ritonavir in an amount of 10.0 to 70.0% by weight and nemategravir in an amount of 30.0 to 90.0% by weight. The present invention can improve the physicochemical properties and processability of pharmaceutical compositions and drugs.